Biotransformation of insulin glargine after subcutaneous injection in healthy subjects.
about
The metabolic and mitogenic properties of basal insulin analoguesSupramolecular Protein Engineering: DESIGN OF ZINC-STAPLED INSULIN HEXAMERS AS A LONG ACTING DEPOTDevelopment of a human breast-cancer derived cell line stably expressing a bioluminescence resonance energy transfer (BRET)-based phosphatidyl inositol-3 phosphate (PIP3) biosensorEffect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance.In vitro metabolic and mitogenic signaling of insulin glargine and its metabolitesInsulin glargine safety in pregnancy: a transplacental transfer study.Dose-response effects of insulin glargine in type 2 diabetes.Glucose-lowering effect of insulin degludec is independent of subcutaneous injection region.Glargine safety, diabetes and cancer.Insulin glargine and risk of cancer: a meta-analysis.Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml.Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarlyInsulin glargine: a reevaluation of rodent carcinogenicity findings.Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence.Basal insulin treatment in type 2 diabetes.Insulin therapy and cancer in type 2 diabetes.Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetesGlargine and cancer: can we now suggest closure?Differences in metabolic and mitogenic signallingof insulin glargine and AspB10 human insulin in rats [corrected].Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and igf-I receptor signaling.Lipoatrophy associated with the use of insulin analogues: a new case associated with the use of insulin glargine and review of the literature.Disorders of glucose metabolism: post mortem analyses in forensic cases--part II.A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations.Metabolism of biologics: biotherapeutic proteins.Basal insulin analogues in the management of diabetes mellitus: What progress have we made?Advances in the quantitation of therapeutic insulin analogues by LC-MS/MS.Insulin glargine metabolite 21(A) -Gly-human insulin (M1) is the principal component circulating in the plasma of young children with type 1 diabetes: results from the PRESCHOOL study.New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus.The past, present, and future of basal insulins.Prevention of tumour cell apoptosis associated with sustained protein kinase B phosphorylation is more sensitive to regulation by insulin signalling than stimulation of proliferation and extracellular signal-regulated kinase.Effect of insulin analogues on phosphatidyl inositol-3 kinase/Akt signalling in INS-1 rat pancreatic derived β-cells.Euglycaemic glucose clamp: what it can and cannot do, and how to do it.Tissue barriers and novel approaches to achieve hepatoselectivity of subcutaneously-injected insulin therapeutics.Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL.New insights into antidiabetic drugs: Possible applications in cancer treatment.Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells.Direct comparison of radioimmunoassay and LC-MS/MS for PK assessment of insulin glargine in clinical development.Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes.Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function.
P2860
Q26991486-8AF794A7-6C1D-4368-A365-52CCE4D1EC39Q27660044-937EA682-00B6-41BF-AAAD-63F7BC308383Q28541161-63A18D41-66ED-4FCF-A66D-9EBB26DAAA58Q28728738-3053A685-6F7F-400B-A5B2-C2070FE56DD7Q30248803-4189B666-5CAF-43F2-A1D1-E29C33C4BEC9Q33537987-6900B036-224E-48ED-99BE-1A859342AC57Q33556840-13A0E502-154E-40C0-B2C1-DF7BC04A274DQ33932753-E2A97E1A-5E85-47BB-AC64-25EE35463F38Q34085107-BE94DA05-E0D0-44B4-A5AE-B90B3942C601Q34326924-A11B0770-6CF9-4697-B0A2-2A0DE2AAFFA0Q34366858-54BB905D-B1A6-4556-A3AE-DDC509E98712Q34543063-70EF9FE3-6ED2-4376-904B-26B31F70D8AEQ35809936-164BC3F2-01EB-48A6-903A-96647F702CE8Q35886868-3F0C3ECF-6B8E-4F93-A9D3-0A39CAB35257Q35937961-51724C97-2B85-4E32-878E-C49605A0D6C7Q36417426-1D79D98E-0E65-4147-9619-E04F098FE7D1Q36417868-14D8E539-76C3-4FB1-B235-A5FF9242874DQ36426750-7A1BFC4C-582F-440C-ADBE-4AF9A554BCC4Q36426885-E1E61588-0179-477F-A0C8-04199C6A2C49Q36976992-126EC5A7-83E1-4AE9-9B0A-7B840086F5DAQ37014889-C899C967-E63D-4ED4-9257-3F8D226FF875Q37650588-8CF9330D-BE58-4299-AC40-F789E8CE5055Q37798480-1E88D21A-E3B5-4436-BF7C-40781D54AB7BQ37853658-6E1E35B3-264D-451C-BC69-DA69B4B6A266Q37976442-70EE4486-E177-4CFB-B70E-84966C0B2AB1Q38136581-901F353B-A15E-42B2-BDDB-7A67BA1DDCB3Q38167831-BAA86216-9964-4790-9C81-483EBCBCA90AQ38426608-78A8AA1C-752E-4ACB-A068-A98626A290D1Q38559945-E20B788A-AB9D-43E2-AEC8-DEE916EB1A17Q38618376-D7FC044F-96B4-4CBB-846C-DA86F0708A1CQ38711630-E9B47E3A-542B-4725-9832-02E677135A73Q38808885-1C6CEF72-8AD2-4B99-8D7A-34138902BBEBQ38871135-2A2D5853-145E-4154-A05D-63713B25A3ADQ38881426-F10DCCE1-6738-4A04-9F62-8B6D63CBB9CCQ38971612-BB73D5F8-337F-4D7E-9BAF-5BEC65142B3AQ39272833-7CB334C3-D682-474B-BE82-78102004281AQ39732794-B47375A7-D0C8-44FC-850E-60C91B6F0A5BQ41656524-2C9AC36D-A0F8-4545-A617-F7E1B929296FQ41825022-277104E5-0347-4FC0-8CCB-88DEE9679EFCQ41887004-CB3CF795-6603-435D-9609-03FCA7FE435F
P2860
Biotransformation of insulin glargine after subcutaneous injection in healthy subjects.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Biotransformation of insulin glargine after subcutaneous injection in healthy subjects.
@en
Biotransformation of insulin glargine after subcutaneous injection in healthy subjects.
@nl
type
label
Biotransformation of insulin glargine after subcutaneous injection in healthy subjects.
@en
Biotransformation of insulin glargine after subcutaneous injection in healthy subjects.
@nl
prefLabel
Biotransformation of insulin glargine after subcutaneous injection in healthy subjects.
@en
Biotransformation of insulin glargine after subcutaneous injection in healthy subjects.
@nl
P2093
P1476
Biotransformation of insulin glargine after subcutaneous injection in healthy subjects.
@en
P2093
Bernhardt E
Kuerzel GU
Potgieter MA
Pretorius SG
Scholtz HE
Wessels DH
P356
10.1185/030079902125001416
P407
P577
2003-01-01T00:00:00Z